Drugs that contain Darunavir
1. Drug name - PREZISTA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(1 year, 4 months from now) | |
| US7700645 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Dec, 2026
(4 years from now) | |
| CN1668623A | JANSSEN PRODS | A Pseudo-Polymorphic Hiv Protease Inhibitor |
May, 2023
(7 months from now) | |
| CN100475819C | JANSSEN PRODS | A Pseudo-Polymorphic Hiv Protease Inhibitor |
May, 2023
(7 months from now) | |
| EP2767539A1 | JANSSEN PRODS | Pseudopolymorphic Forms Of A Hiv Protease Inhibitor |
May, 2023
(7 months from now) | |
| EP3045460A1 | JANSSEN PRODS | Pseudopolymorphic Forms Of A Hiv Protease Inhibitor |
May, 2023
(7 months from now) | |
| EP1567529B2 | JANSSEN PRODS | Pseudopolymorphic Forms Of A Hiv Protease Inhibitor |
May, 2023
(7 months from now) | |
| EP1567529B1 | JANSSEN PRODS | Pseudopolymorphic Forms Of A Hiv Protease Inhibitor |
May, 2023
(7 months from now) | |
| EP2314591B2 | JANSSEN PRODS | Pseudopolymorphic Forms Of A Hiv Protease Inhibitor |
May, 2023
(7 months from now) | |
| EP2314591A1 | JANSSEN PRODS | Pseudopolymorphic Forms Of A Hiv Protease Inhibitor |
May, 2023
(7 months from now) | |
| EP1567529A2 | JANSSEN PRODS | Pseudopolymorphic Forms Of A Hiv Protease Inhibitor |
May, 2023
(7 months from now) | |
| EP2314591B1 | JANSSEN PRODS | Pseudopolymorphic Forms Of A Hiv Protease Inhibitor |
May, 2023
(7 months from now) | |
| EP3045460B1 | JANSSEN PRODS | Pseudopolymorphic Forms Of A Hiv Protease Inhibitor |
May, 2023
(7 months from now) | |
| EP2767539B1 | JANSSEN PRODS | Pseudopolymorphic Forms Of A Hiv Protease Inhibitor |
May, 2023
(7 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8518987
(Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Aug, 2024
(1 year, 10 months from now) | |
|
US7700645
(Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Jun, 2027
(4 years from now) | |
Treatment: NA
Dosage: SUSPENSION;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 100MG/ML | SUSPENSION;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.